Ligand Pharmaceuticals (LGND) Competitors $135.83 +3.00 (+2.26%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$135.91 +0.08 (+0.06%) As of 07/25/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LGND vs. ADMA, ANIP, EXAS, MDGL, HALO, RGEN, IONS, ALKS, FOLD, and BCRXShould you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "medical" sector. Ligand Pharmaceuticals vs. Its Competitors ADMA Biologics ANI Pharmaceuticals Exact Sciences Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Ionis Pharmaceuticals Alkermes Amicus Therapeutics BioCryst Pharmaceuticals Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has preferable earnings & valuation, LGND or ADMA? ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M15.68-$4.03M-$7.12-19.08ADMA Biologics$426.45M10.08$197.67M$0.8521.19 Does the media favor LGND or ADMA? In the previous week, ADMA Biologics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 8 mentions for ADMA Biologics and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat ADMA Biologics' score of 0.85 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, LGND or ADMA? Ligand Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Is LGND or ADMA more profitable? ADMA Biologics has a net margin of 45.01% compared to Ligand Pharmaceuticals' net margin of -73.07%. ADMA Biologics' return on equity of 47.16% beat Ligand Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-73.07% -7.83% -6.92% ADMA Biologics 45.01%47.16%30.51% Do institutionals & insiders hold more shares of LGND or ADMA? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend LGND or ADMA? Ligand Pharmaceuticals currently has a consensus price target of $147.17, suggesting a potential upside of 8.35%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 53.62%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryADMA Biologics beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGND vs. The Competition Export to ExcelMetricLigand PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.62B$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E RatioN/A21.3228.3920.07Price / Sales15.68270.06427.4498.54Price / Cash84.5342.7636.2258.56Price / Book3.098.378.675.88Net Income-$4.03M-$55.19M$3.25B$258.89M7 Day Performance-2.35%5.86%4.30%3.70%1 Month Performance17.41%17.29%10.57%11.71%1 Year Performance26.78%4.39%35.68%17.98% Ligand Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGNDLigand Pharmaceuticals3.5351 of 5 stars$135.83+2.3%$147.17+8.3%+28.1%$2.62B$167.13M0.0080ADMAADMA Biologics3.6008 of 5 stars$17.04-3.1%$27.67+62.4%+37.7%$4.07B$426.45M20.06530News CoverageANIPANI Pharmaceuticals3.8571 of 5 stars$67.58-0.7%$78.88+16.7%+8.8%$1.46B$614.38M-53.20600Positive NewsEXASExact Sciences4.7431 of 5 stars$52.01-0.4%$70.50+35.6%+0.3%$9.82B$2.76B-9.457,000News CoveragePositive NewsMDGLMadrigal Pharmaceuticals4.3127 of 5 stars$338.14-3.0%$420.63+24.4%+5.3%$7.51B$180.13M-18.7390News CoverageInsider TradeHALOHalozyme Therapeutics4.8504 of 5 stars$57.38-0.7%$62.70+9.3%+4.1%$7.05B$1.02B15.22390Positive NewsRGENRepligen4.6366 of 5 stars$121.01-2.4%$170.75+41.1%-8.0%$6.83B$634.44M-270.151,778Upcoming EarningsAnalyst UpgradeIONSIonis Pharmaceuticals4.5354 of 5 stars$42.04-0.3%$57.13+35.9%-18.5%$6.68B$705M-14.051,069News CoverageUpcoming EarningsALKSAlkermes4.7817 of 5 stars$29.44+0.3%$40.92+39.0%-6.8%$4.85B$1.56B14.081,800Upcoming EarningsFOLDAmicus Therapeutics4.0511 of 5 stars$6.16-2.1%$16.22+163.6%-40.9%$1.90B$528.29M-68.38480News CoverageUpcoming EarningsBCRXBioCryst Pharmaceuticals4.4364 of 5 stars$8.69-0.1%$16.70+92.2%+13.2%$1.81B$450.71M-33.25530Analyst Upgrade Related Companies and Tools Related Companies ADMA Competitors ANIP Competitors EXAS Competitors MDGL Competitors HALO Competitors RGEN Competitors IONS Competitors ALKS Competitors FOLD Competitors BCRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGND) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.